Antifibrotic Effects of Pirfenidone in Rat Proximal Tubular Epithelial Cells

REFERENCES

• Eddy AA. Progression in chronic kidney disease. Adv Chronic Kidney Dis. 2005;12:353–365.
   PubMed Web of Science ®Google Scholar
• Boor P, Ostendorf T, Floege J. Renal fibrosis: Novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol. 2010;6:643–656.
   PubMed Web of Science ®Google Scholar
• Negri AL. Prevention of progressive fibrosis in chronic renal diseases: Antifibrotic agents. J Nephrol. 2004;17:496–503.
   PubMed Web of Science ®Google Scholar
• Declèves AE, Sharma K. New pharmacological treatments for improving renal outcomes in diabetes. Nat Rev Nephrol. 2010;6:371–380.
   PubMed Web of Science ®Google Scholar
• Wight TN, Potter-Perigo S. The extracellular matrix: An active or passive player in fibrosis? Am J Physiol. 2011;301:G950–G955.
   PubMed Web of Science ®Google Scholar
• Sharma SK, Ziyadeh FN. The emerging role of transforming growth factor-beta in kidney diseases. Am J Physiol. 1994;266:F829–F842.
   PubMed Web of Science ®Google Scholar
• Gagliardini E, Benigni A. Therapeutic potential of TGF-beta inhibition in chronic renal failure. Expert Opin Biol Ther. 2007;7:293–304.
   PubMed Web of Science ®Google Scholar
• Ma LJ, Fogo AB. PAI-1 and kidney fibrosis. Front Biosci. 2009;14:2028–2041.
   Web of Science ®Google Scholar
• Eddy AA. Serine proteases, inhibitors and receptors in renal fibrosis. Thromb Hemost. 2009;101:656–664.
   PubMed Web of Science ®Google Scholar
• Fan JM, Ng YY, Hill PA, . Transforming growth factor-beta regulates tubular epithlial-myofibroblast transdifferentiation in vitro. Kidney Int. 1999;56:1455–1467.
   PubMed Web of Science ®Google Scholar
• Burns WC, Kantharidis P, Thomas MC. The role of tubular epithelial-mesenchymal transition in progressive kidney disease. Cells Tissues Organs. 2007;185:222–231.
   PubMed Web of Science ®Google Scholar
• Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol. 2010;21:212–222.
   PubMed Web of Science ®Google Scholar
• Fukasawa H, Yamamoto T, Suzuki H, . Treatment with anti-TGF-β antibody ameliorates chronic progressive nephritis by inhibiting Smad/TGF-β signaling. Kidney Int. 2004;65:63–74.
   PubMed Web of Science ®Google Scholar
• Taniguchi H, Ebina M, Kondoh Y, . Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35:821–829.
   PubMed Web of Science ®Google Scholar
• Maher TM. Pirfenidone in idiopathic pulmonary fibrosis. Drugs Today. 2010;46:473–482.
   PubMed Web of Science ®Google Scholar
• Macias-Barragan J, Sandoval-Rodriguez A, Navarro-Partida J, Armendariz-Borunda J. The multifaceted role of pirfenidone and its novel targets. Fibrogenesis Tiss Rep. 2010;3:16.
   PubMedGoogle Scholar
• Shimizu T, Kuroda T, Hata S, Fukagawa M, Margolin SB, Kurokawa K. Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int. 1998;54:99–109.
   PubMed Web of Science ®Google Scholar
• Shimizu T, Fukagawa M, Kuroda T, . Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. Kidney Int Suppl. 1997;63:S239–S243.
   PubMed Web of Science ®Google Scholar
• Takakura K, Fujimori A, Chikanishi T, . Renoprotective properties of pirfenidone in subtotally nephrectomized rats. Eur J Pharmacol. 2010;629:118–124.
   PubMed Web of Science ®Google Scholar
• Iyer SN, Wild JS, Schiedt MJ, Hyde DM, Margolin SB, Giri SN. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med. 1995; 125:779–785.
   PubMed Web of Science ®Google Scholar
• Nakayama S, Mukae H, Sakamoto N, . Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts. Life Sci. 2008;82:210–217.
   PubMed Web of Science ®Google Scholar
• Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev. 2011;20:85–97.
   PubMedGoogle Scholar
• Floege J, Eitner F, Alpers CE. A new look at platelet-derived growth factor in renal disease. J Am Soc Nephrol. 2008;19:12–23.
   PubMed Web of Science ®Google Scholar
• Ostendorf T, Kunter U, Grone HJ, . Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis. J Am Soc Nephrol. 2001;12:909–918.
   PubMed Web of Science ®Google Scholar
• Ostendorf T, Eitner F, The FJ. PDGF family in renal fibrosis. Pediatr Nephrol. 2011;26(9):2728–2731 (online).
   Google Scholar
• Yamate J. Heterogeneity of macrophage populations and myofibroblasts appearing in rat renal interstitial fibrosis. J Toxicol Pharmacol. 2007;20:185–195.
   Google Scholar
• Shimizu F, Fukagawa M, Yamauchi S, . Pirfenidone prevents the progression of irreversible glomerular sclerotic lesions in rats. Nephrology. 1997;3:315–322.
   Web of Science ®Google Scholar
• Hammes MS, Lieske JC, Pawar S, Spargo BH, Toback FG. Calcium oxalate monohydrate crystals stimulate gene expression in renal epithelial cells. Kidney Int. 1995;48:501–509.
   PubMed Web of Science ®Google Scholar
• Zhang G, Kim H, Cai X, Lopez-Guisa JM, Carmeliet P, Eddy AA. Urokinase receptor modulates cellular and angiogenic responses in obstructive nephropathy. J Am Soc Nephrol. 2003; 14:1234–1253.
   PubMed Web of Science ®Google Scholar
• Eddy AA. Molecular basis of renal fibrosis. Pediatr Nephrol. 2000;15:290–301.
   PubMed Web of Science ®Google Scholar
• Ma J, Weisberg A, Griffin JP, Vaughan DE, Fogo AB, Brown NJ. Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney Int. 2006; 69:1064–1072.
   PubMed Web of Science ®Google Scholar
• Shihab FS, Bennett WM, Yi H, Andoh TF. Pirfenidone treatment decreases transforming growth factor-β1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity. Am J Transplant. 2002;2:111–119.
   PubMed Web of Science ®Google Scholar
• Ikushima H, Komuro A, Isogaya K, . An Id-like molecule, HHM, is a synexpression group-restricted regulator of TGF-β signaling. EMBO J. 2008;27:2955–2965.
   PubMed Web of Science ®Google Scholar
• Schiller M, Dennler S, Anderegg U, . Increased cAMP levels modulate transforming growth factor-beta/Smad-induced expression of extracellular matrix components and other key fibroblast effector functions. J Biol Chem. 2010;285:409–421.
   PubMed Web of Science ®Google Scholar
• Samarakoon R, Higgins PJ. Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells. Thromb Hemost. 2008;100:976–983.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Feng XH, Derynck R. Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription. Nature. 1998;27:909–913.
   Google Scholar
• Ozes ON, Stevens SK, Phillips RJ, Blatt LM. Pirfenidone attenuates transforming growth factor-beta-induced activation of P38-alpha and P38-gamma mitogen-activated protein kinases in human lung fibroblasts: Implications for treatment of fibrotic lung diseases. Chest. 2006;130:114S (Abstract).
   Web of Science ®Google Scholar
• Cirit M, Wang CC, Haugh JM. Systematic quantification of negative feedback mechanisms in the extracellular signal-regulated kinase (ERK) signaling network. J Biol Chem. 2010;285:36736–36744.
   PubMed Web of Science ®Google Scholar
• Frazier KS, Paredes A, Dube P, Styer E. Connective tissue growth factor expression in the rat remnant kidney model and association with tubular epithelial cells undergoing transdifferentiation. Vet Pathol. 2000;37:328–335.
   PubMed Web of Science ®Google Scholar
• Sommer M, Eismann U, Deuther-Conrad W, . Time course of cytokine mRNA expression in kidneys of rats with unilateral ureteral obstruction. Nephron. 2000;84:49–57.
   PubMed Web of Science ®Google Scholar
• Creely JJ, Dimari SJ, Howe AM, Haralson MA. Effects of transforming growth factor-beta on collagen synthesis by normal rat kidney epithelial cells. Am J Pathol. 1992;140:45–55.
   PubMed Web of Science ®Google Scholar
• Kisseleva T, Brenner DA. Mechanisms of fibrogenesis. Exp Biol Med. 2008;233:109–122.
   PubMed Web of Science ®Google Scholar
• Yuan Q, Wang L, Zhang F, . Fluorofenidone suppresses epithelial-mesenchymal transition and the expression of connective tissue growth factor via inhibiting TGF-β/Smads signaling in human proximal tubular epithelial cells. Pharmazie. 2011;66:961–967.
   PubMed Web of Science ®Google Scholar
• Grgic I, Duffield JS, Humphreys BD. The origin of interstitial myofibroblasts in chronic kidney disease. Pediatr Nephrol. 2012;27:183–193.
   Google Scholar